Apparent KIT Ser(715) deletion in GIST mRNA is not detectable in genomic DNA and represents a previously known splice variant of KIT transcript.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

1. Phase II trial of imatinib mesylate in patients with metastatic melanoma.British journal of cancer · 2008
   Trial
2. Repression of c-kit and its downstream substrates by GATA-1 inhibits cell proliferation during erythroid maturation.Molecular and cellular biology · 2005
   Article

Corrections and comments

• Comment on
  The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors.2002

Authors and funding

5 authors at 2 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as